RZLT Share Price Performance
US$9.10
4.32 (90.38%)
Price US$9.10
Share PriceUS$9.10
Rezolute, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
RZLT Community Narratives
There are no narratives available yet.
Rezolute, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.82
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Rezolute, Inc. Competitors
Snowflake Analysis
About RZLT
- Founded
- 2010
- Employees
- 71
- CEO
- WebsiteView website
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.2%
- 3 Months: 8.5%
- 1 Year: 17.7%
- Year to Date: 14.8%
Over the last 7 days, the market has risen 1.2%, driven by gains of 2.4% in the Information Technology sector. The market is up 18% over the last 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›